Unicycive therapeutics.

LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has ...Investors - Unicycive. [WE DO NOT CONTROL THIS SECTION OF THE SITE. WE WILL CONNECT WITH THE THIRD PARTY BUT MAY NEED TO CREATE THE HEADER IMAGE. THIS COULD BE A MAGNIFYING GLASS MADE OUT OF DOTS.] [WE DO NOT CONTROL THIS SECTION OF THE SITE.LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has entered a licensing agreement with Spectrum Pharmaceuticals for Renazorb (lanthanum dioxycarbonate), a late-stage asset for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).Unicycive Therapeutics, Inc. March 31, 2023 at 7:00 AM · 11 min read. Unicycive Therapeutics, Inc. Closed transformational fundraise that included $30 million financing upfront with up to an ...

Listen to Audio Version. The global hyperphosphatemia treatment market size was USD 2.36 billion in 2020 and is projected to reach USD 3.53 billion in 2028, at a CAGR of 5.3% in the 2021-2028 period. The global market witnessed a growth of 2.0% in the year 2020, as compared to the average year-on-year growth during 2017-2019.Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a novel phosphate binding agent being ...6 Jul 2023 ... Unicycive Therapeutics Inc. (NASDAQ: UNCY). Latest News. About US. Overview · Team · The RedChip Way · Why CEO's Hire RedChip ...

Unicycive Therapeutics, Inc. announced that it has signed an agreement issue 130,000 series A convertible preferred shares at an issue price of $1,000 per share for gross proceeds of up to $130 million on March 3, 2023.Unicycive Therapeutics, Inc. (UNCY.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Unicycive Therapeutics, ...

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18 ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational ...18 Jul 2022 ... Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. ... SOURCE: Unicycive Therapeutics, Inc.Aarvik Therapeutics is pursuing exciting molecules with an improved therapeutic index for several oncology targets by combining novel modular antibody platforms with multiple target mechanisms. Aarvik antibody platforms are readily manufacturable, scalable and versatile, and offer unlimited potential through modular design. ...Pharmaceutical and Business Operations, Unicycive Therapeutics, Inc., Los Altos, California, USA. PMID: 37231835; PMCID: PMC10614253; DOI: 10.1159/000530989 ...

2022年7月18日，生物技术公司Uncycive Therapeutics与李氏大药厂签订协议，授予后者于中国大陆、香港及若干其他亚洲市场开发、营销和商业化Renazorb（二氧碳酸镧）的独家权利。根据协议，Unicycive公司将于协议签订时收取100万美元的预付账款，并于产品在中国推出时收取最多100万美元的里程碑款项。

Therapeutic Focus · Pipeline · UNI-494 · Oxylanthanum Carbonate (OLC) · Investors ... Prior to joining Unicycive, he worked at Spectrum Pharmaceuticals for 15 ...

Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022) Unicycive Therapeutics ( NASDAQ:UNCY ) Third Quarter 2023 Results Key Financial Results Net ...About Unicycive Therapeutics, Inc. Unicycive is focused on two kidney diseases with large unmet medical needs. We are developing Renazorb, an investigational phosphate binding agent using ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...SCAI-003 Sunitinib. Wet age-related macular degeneration (wet AMD) is a disastrous disease of vision impairment in the macular region of the retina due to abnormalUnicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT ...Legal Name Unicycive Therapeutics, Inc. Stock Symbol NASDAQ:UNCY. Company Type For Profit. Phone Number (650) 384-0642. Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the ... Unicycive Therapeutics, Inc. (UNCY) latest earnings report: revenue, EPS, surprise, history, news and analysis.30 Oct 2023 ... 4 likes, 0 comments - b2i_digital on October 30, 2023: "Unicycive Therapeutics (Nasdaq: $UNCY), a B2i Digital Featured Company, ...Unicycive Therapeutics Inc (UNCY) $0.49 0.01 (2.47%) 15:59 EST UNCY Stock Quote Delayed 30 Minutes The 7 Most Undervalued Penny Stocks to Buy in October 2023.

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on …

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing …Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology diseases, two large and fast-growing therapeutic areas. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma …Nov 30, 2023 · Unicycive Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume. Change versus previous month Short interest in Unicycive Therapeutics has recently increased by 18.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0. As of December 4, 2023, Unicycive Therapeutics (NASDAQ: UNCY) has received positive analyst coverage and recommendations. Bruce Jackson from Benchmark has …Unicycive Therapeutics Inc. published this content on 03 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2022 09:31:06 UTC.Track Unicycive Therapeutics Inc (UNCY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsUnicycive Therapeutics is bordering on breakeven, according to the 5 American Biotechs analysts. They expect the company to post a final loss in 2024, before turning a profit of US$154m in 2025.View the latest Unicycive Therapeutics Inc. (UNCY) stock price, news, historical charts, analyst ratings and financial information from WSJ.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

LOS ALTOS, Calif., Nov. 11, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for …

212-362-1200. SOURCE: Unicycive Therapeutics, Inc. $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo …

About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is ...UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology diseases, two large and fast-growing therapeutic areas. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma …John Townsend. John Townsend is Chief Financial Officer at Unicycive Therapeutics Inc. Previously, he has served as Vice President of Finance and Chief Accounting Officer in a consulting role for Unicycive. He has over 25 years of public and private company experience in industries including biotechnology, medical devices, and high-tech ... Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...Sep 6, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Unicycive Therapeutics stock is dropping on an update from regulators.; The Food and Drug Administration (FDA) wants more data on its hyperphosphatemia in chronic kidney disease patients treatment.Unicycive Therapeutics, Inc. (“the Company”) was incorporated in the State of Delaware on August 18, 2016. The Company was dormant until July 2017 when it began evaluating a number of drug candidates for in-licensing. The Company in-licensed the drug candidate UNI 494 from Sphaera Pharma Pte.According to the issued ratings of 4 analysts in the last year, the consensus rating for Unicycive Therapeutics stock is Buy based on the current 4 buy ratings for UNCY. The average twelve-month price prediction for Unicycive Therapeutics is $10.83 with a high price target of $24.00 and a low price target of $4.00.Dec 1, 2023 · Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

Nov 17, 2023 · Unicycive Therapeutics Earnings Insights Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.Dec 29, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Mar 6, 2023 · Item 1.01. Entry into a Material Definitive Agreement. On March 3, 2023, Unicycive Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors (the "Investors"), pursuant to which the Company agreed to issue and sell, in a private placement (the "Offering"), 30,190 shares of Series A-1 Convertible Preferred Stock ... Instagram:https://instagram. mutual fund for goldnasdaq fcel comparebest cryptocurrency day tradingarmanino foods Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs. qcom.stockmedical insurance companies in washington state Unicycive Therapeutics reports Q3 2023 GAAP EPS of -$0.13 and reveals cash and cash equivalents of $14.3 million, projected to last until H2 2024.Laumas has served as a member of the board of directors of Bioxcel Therapeutics Inc. since 2017 and a board member of Unicycive Therapeutics Inc. since 2018. He previously served as a board member of 9 Meters Biopharma, Inc. from 2020-21, its Executive Chairman from 2014-20, including its Chief Executive Officer from 2019-20. best platform to buy pre ipo stocks Nov 17, 2023 · Unicycive Therapeutics Earnings Insights Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent ...